NanoViricides (NYSE:NNVC) Coverage Initiated at

Equities research analysts at started coverage on shares of NanoViricides (NYSE:NNVCGet Rating) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

NanoViricides Price Performance

NNVC stock opened at $1.16 on Monday. NanoViricides has a 52 week low of $1.05 and a 52 week high of $3.88. The firm has a market cap of $13.50 million, a price-to-earnings ratio of -1.93 and a beta of 1.07.

About NanoViricides

(Get Rating)

NanoViricides, Inc is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R.

Recommended Stories

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with's FREE daily email newsletter.